Calluna Pharma

Executive Summary

Calluna Pharma is a Norway-based biotechnology company founded in 2020, focused on developing first-in-class antibody therapeutics for inflammatory and fibrotic diseases. The company was formed by the merger of Arxx Therapeutics and Oxitope Pharma, combining expertise in targeting upstream innate immune amplifiers. Its lead program, CAL101, is a Phase 2 candidate for Idiopathic Pulmonary Fibrosis (IPF) developed in partnership with Eli Lilly. Calluna is positioned to address significant unmet medical needs in fibrotic diseases, leveraging its innovative approach to modulate the innate immune system. The company is privately held and has not disclosed total funding, but its partnership with Lilly provides validation and potential for accelerated development. With a focus on first-in-class mechanisms, Calluna represents a promising player in the immunology and fibrosis space, though it remains early-stage with clinical data yet to be reported.

Upcoming Catalysts (preview)

• H1 2027Phase 2 interim data for CAL101 in IPF45% success
• H2 2026Initiation of Phase 2 trial for second indication (e.g., systemic sclerosis)60% success
• 2026Potential partnership or licensing deal for pipeline assets50% success